These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18071694)

  • 1. Nephrogenic systemic fibrosis.
    Martin DR
    Pediatr Radiol; 2008 Jan; 38 Suppl 1():S125-9. PubMed ID: 18071694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
    Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases.
    Zou Z; Zhang HL; Roditi GH; Leiner T; Kucharczyk W; Prince MR
    JACC Cardiovasc Imaging; 2011 Nov; 4(11):1206-16. PubMed ID: 22093272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrogenic systemic fibrosis: center case review.
    Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
    J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium.
    Cowper SE
    Adv Dermatol; 2007; 23():131-54. PubMed ID: 18159899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nephrogenic systemic fibrosis as an adverse drug reaction of gadolinium-based contrast media for magnetic resonance imaging].
    Giersig C
    Radiologe; 2007 Sep; 47(9):794-9. PubMed ID: 17713753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nephrogenic systemic fibrosis and gadolinium-based contrast media].
    Andréjak M; Thuillier D; Lok C; Gras-Champel V
    Therapie; 2007; 62(2):169-72. PubMed ID: 17582319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention.
    Bäuerle T; Saake M; Uder M
    Rofo; 2021 Sep; 193(9):1010-1018. PubMed ID: 33348385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016.
    Endrikat J; Dohanish S; Schleyer N; Schwenke S; Agarwal S; Balzer T
    Invest Radiol; 2018 Sep; 53(9):541-550. PubMed ID: 29547493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
    Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
    Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
    Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
    Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadolinium and nephrogenic systemic fibrosis: association or causation.
    Kurtkoti J; Snow T; Hiremagalur B
    Nephrology (Carlton); 2008 Jun; 13(3):235-41. PubMed ID: 18221255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
    Peak AS; Sheller A
    Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadolinium and nephrogenic systemic fibrosis.
    Grobner T; Prischl FC
    Kidney Int; 2007 Aug; 72(3):260-4. PubMed ID: 17507905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
    Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
    Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment.
    Alfano G; Fontana F; Ferrari A; Solazzo A; Perrone R; Giaroni F; Torricelli P; Cappelli G
    Magn Reson Imaging; 2020 Jul; 70():1-4. PubMed ID: 32112811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.
    Perez-Rodriguez J; Lai S; Ehst BD; Fine DM; Bluemke DA
    Radiology; 2009 Feb; 250(2):371-7. PubMed ID: 19188312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
    Sadowski EA; Bennett LK; Chan MR; Wentland AL; Garrett AL; Garrett RW; Djamali A
    Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.